- Home
- TLPH vs ATNM Comparison
TLPH vs ATNM Comparison
Compare TLPH & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | ATNM |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 45.2M |
| IPO Year | 2010 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TLPH | ATNM |
|---|---|---|
| Price | $0.92 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 227.4K | 113.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $1.02 |
| 52 Week High | $1.57 | $1.95 |
Technical Indicators
Market Signals| Indicator | TLPH | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 46.79 |
| Support Level | $0.86 | $1.02 |
| Resistance Level | $1.05 | $1.71 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 62.43 | 63.00 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.